Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-09-22
DOI
10.1007/s40259-023-00625-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
- (2023) Atul Deodhar et al. JOURNAL OF RHEUMATOLOGY
- Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
- (2022) Sanjay Chabra et al. ADVANCES IN THERAPY
- Spectrum of Spondyloarthritis Among Chinese Populations
- (2022) Shangzhu Zhang et al. Current Rheumatology Reports
- Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study
- (2022) Xia Li et al. International Journal of Dermatology and Venerology
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- (2022) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluating the strength of spinal and proximal girdle muscles in patients with axial spondyloarthritis: Correlation with activity, disability, and functionality
- (2021) Ozan Volkan Yurdakul et al. International Journal of Rheumatic Diseases
- Axial spondyloarthritis
- (2021) Victoria Navarro-Compán et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
- (2020) Mark C Genovese et al. RHEUMATOLOGY
- Ixekinumab for the treatment of ankylosing spondylitis
- (2020) Jin-Xian Huang et al. Expert Review of Clinical Immunology
- Treatment strategies in axial spondyloarthritis: what, when and how?
- (2020) George E Fragoulis et al. RHEUMATOLOGY
- 2018 APLAR axial spondyloarthritis treatment recommendations
- (2019) Lai Shan Tam et al. International Journal of Rheumatic Diseases
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2019) Michael M. Ward et al. Arthritis & Rheumatology
- Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- (2019) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
- (2018) Pedro M Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of treatment options for spondyloarthritis: a narrative review
- (2018) Salvatore D’Angelo et al. Expert Opinion On Drug Safety
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
- (2017) Désirée van der Heijde et al. JOURNAL OF RHEUMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
- (2016) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis
- (2016) Carmen Stolwijk et al. ARTHRITIS CARE & RESEARCH
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
- (2013) R Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents
- (2012) Xin Gao et al. JOURNAL OF MEDICAL ECONOMICS
- Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Sp
- (2011) Jane Zochling ARTHRITIS CARE & RESEARCH
- A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis
- (2010) R. D. INMAN et al. JOURNAL OF RHEUMATOLOGY
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
- (2009) J Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started